Abstract:Background: Hepatoblastoma (HB) is the most common pediatric liver tumor, presenting significant therapeutic challenges due to its high rates of recurrence and metastasis. While Inosine Monophosphate Dehydrogenase 2(IMPDH2) has been associated with cancer progression, its specific role and clinical implications in HB have not been fully elucidated. Methods: This study utilized Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) and Tissue Microarray (TMA) for validation. Following this, IMPDH2 was suppressed, and a series of in vitro assays were conducted. Flow cytometry was employed to assess apoptosis and cell cycle arrest. Additionally, the study explored the synergistic therapeutic effects of mycophenolate mofetil (MMF) and doxorubicin (DOX) on HB cell lines. Results: The study identified a marked overexpression of IMPDH2 in HB tissues, which was strongly correlated with reduced Overall Survival (OS) and Event-Free Survival (EFS). IMPDH2 upregulation was also found to be associated with key clinical-pathological features, including pre-chemotherapy alpha-fetoprotein (AFP) levels, presence of preoperative metastasis, and the pre-treatment extent of tumor (PRETEXT) staging system. Knockdown of IMPDH2 significantly inhibited HB cell proliferation and tumorigenicity, inducing cell cycle arrest at the G0/G1 phase. Notably, the combination of MMF, identified as a specific IMPDH2 inhibitor, with DOX, substantially enhanced the therapeutic response. Conclusion: The overexpression of IMPDH2 was closely linked to adverse outcomes in HB patients and appeared to accelerate cell cycle progression. These findings suggest that IMPDH2 may serve as a valuable prognostic indicator and a potential therapeutic target for HB. Impact: The present study unveiled a significant overexpression of inosine monophosphate dehydrogenase 2 (IMPDH2) in hepatoblastoma (HB) tissues, particularly in association with metastasis and recurrence of the disease. The pronounced upregulation of IMPDH2 was found to be intimately correlated with adverse outcomes in HB patients. This overexpression appears to accelerate the progression of the cell cycle, suggesting that IMPDH2 may serve as a promising candidate for both a prognostic marker and a therapeutic target in the context of HB.

Enhancer of Zeste Homolog 2 Depletion Arrests the Proliferation of Hepatoblastoma Cells.

Polycomb Protein Ezh2 Activates Wnt/Beta-Catenin Signaling To Promote Hepatocellular Carcinoma Development

Sorafenib Suppresses Growth and Survival of Hepatoma Cells by Accelerating Degradation of Enhancer of Zeste Homolog 2

The correlation of EZH2 expression with the progression and prognosis of hepatocellular carcinoma

Treating human cancer by targeting EZH2

Alteration of the tumor microenvironment by pharmacological inhibition of EZH2 in hepatocellular carcinoma

EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma

Identification of Prognostic miRNAs Targeting EZH2 in Hepatocellular Carcinoma Using The Cancer Genome Atlas Database

EZH2: a novel target for cancer treatment

Clinical Significance of Upregulation of EZH1 Expression in Hepatocellular Carcinoma Tissues

An E2F1/DDX11/EZH2 Positive Feedback Loop Promotes Cell Proliferation in Hepatocellular Carcinoma

Ezh2 Promotes Cell Migration And Invasion But Not Alters Cell Proliferation By Suppressing E-Cadherin, Partly Through Association With Malat-1 In Pancreatic Cancer

Enhancer of Zeste Homolog 2 (EZH2) Promotes Tumour Cell Migration and Invasion Via Epigenetic Repression of E-cadherin in Renal Cell Carcinoma.

EZH2 is Overexpressed in Laryngeal Squamous Cell Carcinoma and Enhances the Stem-Like Properties of AMC-HN-8 Cells

UBE2T Promotes Proliferation Via G2/M Checkpoint in Hepatocellular Carcinoma

EZH2 regulates PD-L1 expression via HIF-1α in non-small cell lung cancer cells

Discovery of IHMT-EZH2-115 as a Potent and Selective Enhancer of Zeste Homolog 2 (EZH2) Inhibitor for the Treatment of B-Cell Lymphomas

IMPDH2 suppression impedes cell proliferation by instigating cell cycle arrest and stimulates apoptosis in pediatric hepatoblastoma

EZH2 represses target genes through H3K27-dependent and H3K27-independent mechanisms in hepatocellular carcinoma.

Targeted Disruption of the EZH 2 / EED Complex Inhibits EZH 2-Dependent Cancer

Enhancer of Zeste Homolog 2 is Involved in the Proliferation of Endometrial Carcinoma.